Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Development of subtype selective GABAA modulators.

Gerard R Dawson1, Neil Collinson, John R Atack

  • 1Merck Sharp & Dohme Research Laboratories, Terlings Park, Eastwick Road, Essex CM20 1QR, England.

CNS Spectrums
|December 25, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Social dysfunction and default mode network functional integrity in neuropsychiatric disorders: A cross-disorder replication and generalization study.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2026
Same author

The cost-effectiveness of predictive algorithm guided primary antidepressant treatment: economic evaluation of the multinational PReDicT randomised controlled trial.

BJPsych open·2026
Same author

Novel positive allosteric modulators of alpha 5 subunit-containing GABA<sub>A</sub> receptors (α5-GABA<sub>A</sub>Rs) reverse the hyperdopaminergic state in a neurodevelopmental model of schizophrenia.

Schizophrenia research·2026
Same author

Negative allosteric modulation of α5-GABA<sub>A</sub> receptors engages dynamic cortical glutamatergic and GABAergic mechanisms underlying adaptive behavior in mice.

bioRxiv : the preprint server for biology·2026
Same author

Antidepressant drugs have pharmacological- and time-dependent effects on reinforcement learning in healthy volunteers: An 8 weeks randomized double-blind placebo-controlled study.

medRxiv : the preprint server for health sciences·2026
Same author

A PK/PD study on antihyperalgesia by an α2/3-GABA<sub>A</sub> receptor PAM in mice: Lack of tolerance liability and potential involvement of γ1-GABA<sub>A</sub> receptors.

British journal of pharmacology·2026
Same journal

Qualitative Clock-Drawing Errors Across Dementia Etiologies and Mild Cognitive Impairment: A Clinically Interpretable Six-Class Framework.

CNS spectrums·2026
Same journal

Correlation patterns between lifetime mood spectrum, impulsivity, and disordered eating behaviors in candidates to bariatric surgery.

CNS spectrums·2026
Same journal

Do patients and clinicians agree on the essential features of OCD?

CNS spectrums·2026
Same journal

Treatment Instability in Generalized Anxiety Disorder (GAD): A U.S. Real-World Evidence Study.

CNS spectrums·2026
Same journal

Prevalence, Severity and Correlates of Post-traumatic Stress Disorder in 205 Outpatients with Schizophrenia: Results from a Cross-sectional, Observational Study Assessing Diagnoses via the Mini-International Neuropsychiatric Interview.

CNS spectrums·2026
Same journal

Lithium and long-term cognitive outcomes in bipolar disorder and early dementia: a systematic review.

CNS spectrums·2026
See all related articles

Benzodiazepine (BZ) drugs targeting gamma-aminobutyric acid type A (GABAA) receptors effectively treat various conditions. Discovering GABAA receptor subtypes allows for developing targeted anxiolytic drugs with fewer side effects.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Molecular Biology

Background:

  • Drugs modulating gamma-aminobutyric acid (GABA) transmission via benzodiazepine (BZ) sites on gamma-aminobutyric acid type A (GABAA) receptors are widely used for anxiety, epilepsy, and sleep disorders.
  • Despite their efficacy, the precise mechanisms underlying their diverse pharmacological effects remain incompletely understood.
  • Recent research highlights regional variations in GABAA receptor composition, leading to the concept of GABAA receptor subtypes.

Purpose of the Study:

  • To investigate the role of specific GABAA receptor subtypes in mediating the effects of benzodiazepines.
  • To explore the potential for developing subtype-specific ligands with improved therapeutic profiles.

Main Methods:

  • Phenotypic analysis of transgenic knock-in and knock-out mice with altered GABAA receptor sensitivity to benzodiazepines.

Related Experiment Videos

  • Development and testing of subtype-specific GABAA receptor ligands.

    • Main Results:

    • Genetic manipulation confirmed that distinct GABAA receptor subtypes mediate specific benzodiazepine effects, such as anxiolysis and sedation.
    • Subtype-specific ligands were successfully developed, demonstrating retained anxiolytic effects while lacking sedative properties.

    Conclusions:

    • The discovery of GABAA receptor subtypes provides a mechanistic basis for the varied effects of benzodiazepines.
    • Targeting specific GABAA receptor subtypes offers a promising strategy for developing novel anxiolytic compounds with reduced side-effect profiles compared to existing treatments.